Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
-
Korda's lead shrinks to five at LPGA Chevron
-
Favored Renegade draws inside post for Kentucky Derby
-
Barcelona on brink of La Liga triumph, Atletico build confidence
-
Trump cancels Pakistan talks trip, says Iran war on hold
-
Atletico build confidence before Arsenal but Barrios hurt
-
Reiss edges Wiley for Drake title in year's best outdoor mile
-
Magic hold off Pistons for 2-1 series lead
-
Trump orders new, blue surface for Washington's Reflecting Pool
-
Guardiola hails 'extraordinary' Man City reaction to make FA Cup history
-
Arteta in red card rant after Arsenal regain top spot
-
Jihadists, Tuareg rebels, claim attacks across Mali
-
Cummins back as Hyderabad overcome Sooryavanshi's IPL century
-
Man City late show sinks Southampton to reach FA Cup final
-
PSG shrug off Angers to edge closer to Ligue 1 title
-
Al Ahli beat Machida Zelvia to retain Asian Champions League title
-
Barcelona held at Bayern in Women's Champions League semi-finals
-
Arsenal back on top of Premier League, Spurs win
-
Eze rocket fires Arsenal back into top spot in Premier League
-
Man City late show beats Southampton to reach FA Cup final
-
De Zerbi hails Spurs win as key to survival fight
-
Swiatek retires with illness in Madrid Open third round
-
Germany blames Russia for Signal phishing attacks on MPs
-
Barcelona on brink of La Liga triumph with Getafe win
-
Barca on brink of La Liga triumph with Getafe win
-
Teen talent Seixas keen for Pogacar, Evenepoel test in Liege
-
Liverpool close on Champions League but may have seen last of Salah
-
Spurs, West Ham win in battle for Premier League survival
-
Bayern storm back to beat Mainz ahead of PSG clash
-
Late Carbonel penalty lifts Stade past Pau in Top 14
-
Lyon a different proposition for Arsenal this time round, says Giraldez
-
Marc Marquez wins chaotic rain-affected Spanish MotoGP sprint
-
Gunfire in Mali as army battles 'terrorist groups'
-
Gunfire rocks Mali districts, including junta stronghold: witnesses
-
Welsh football icon Ramsey takes on marathon challenge for charity
-
Aussie Rules fires appeals chair over ruling on anti-gay slur
-
Lakers' OT win puts Rockets on brink of NBA playoff elimination
-
From radiation to invasion: a Chernobyl worker's two wars
-
AI firms flex lobbying muscle on both side of Atlantic
-
First female Archbishop of Canterbury to meet Pope Leo
-
Hundreds of firefighters battle Japan forest blazes
-
Lakers down Rockets in overtime for 3-0 series lead, Celtics hold off Sixers
-
US envoys heading to Pakistan for uncertain Iran talks
-
'Hockey is religion': Montreal fans pack church for playoff push
-
Billionaire Elon Musk enters courtroom showdown with OpenAI
-
Crunch nuclear proliferation meeting at UN amid raging global wars
-
Awkward debut for Trump at correspondents' dinner
-
Under blackout threat, Wikimedia reaches compromise with Indonesia
-
'Going to the moon': Irish footballers return to China 50 years after historic tour
-
Spurs' Wembanyama ruled out of game 3 after concussion
-
Palestinians to vote in first elections since Gaza war
Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced it has engaged Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year ended December 31, 2024.
This engagement underscores Bionoid's commitment to robust financial governance and transparency, aligning with its strategic initiatives to enhance market presence and shareholder value.
"We are pleased to welcome Aloba, Awomolo & Partners as our auditors for the 2024 fiscal year," said a spokesperson for Bionoid Pharma Inc. "Their expertise will be instrumental as we advance our financial reporting standards. Following our recent application to uplist to the OTCQB Venture Market, this audit represents a critical step toward achieving a more senior listing and reflects our dedication to providing investors with increased visibility and liquidity."
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.
AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.
Stay Connected:
Website: https://bionoidpharma.com
https://aimaverickintel.com/
OTC Markets: BINP
X (formerly Twitter): @BionoidPharminc
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
A.Malone--AMWN
